173 related articles for article (PubMed ID: 31931755)
1. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.
Liao X; Song G; Xu Z; Bu Y; Chang F; Jia F; Xiao X; Ren X; Zhang M; Jia Q
BMC Cancer; 2020 Jan; 20(1):31. PubMed ID: 31931755
[TBL] [Abstract][Full Text] [Related]
2. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
3. Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
Xiong J; Wu JS; Mao SS; Yu XN; Huang XX
Oncol Rep; 2016 Sep; 36(3):1483-90. PubMed ID: 27460949
[TBL] [Abstract][Full Text] [Related]
4. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.
Que KT; Zhou Y; You Y; Zhang Z; Zhao XP; Gong JP; Liu ZJ
J Exp Clin Cancer Res; 2018 Nov; 37(1):268. PubMed ID: 30400960
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma.
Deng G; Zeng S; Ma J; Zhang Y; Qu Y; Han Y; Yin L; Cai C; Guo C; Shen H
Sci Rep; 2017 Jan; 7():41616. PubMed ID: 28134289
[TBL] [Abstract][Full Text] [Related]
7. CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.
Liao X; Bu Y; Jiang S; Chang F; Jia F; Xiao X; Song G; Zhang M; Ning P; Jia Q
Hepatol Int; 2019 Jul; 13(4):440-453. PubMed ID: 31250351
[TBL] [Abstract][Full Text] [Related]
8. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
[TBL] [Abstract][Full Text] [Related]
9. Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma.
Liao X; Bu Y; Chang F; Jia F; Song G; Xiao X; Zhang M; Ning P; Jia Q
BMC Cancer; 2019 Dec; 19(1):1192. PubMed ID: 31805888
[TBL] [Abstract][Full Text] [Related]
10. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin.
Kuang Y; El-Khoueiry A; Taverna P; Ljungman M; Neamati N
Mol Oncol; 2015 Nov; 9(9):1799-814. PubMed ID: 26160429
[TBL] [Abstract][Full Text] [Related]
11. Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-β-catenin-ABCG1 signaling pathway.
Liao X; Zhang Y; Xu B; Ali A; Liu X; Jia Q
J Cancer; 2021; 12(20):6071-6080. PubMed ID: 34539880
[TBL] [Abstract][Full Text] [Related]
12. β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.
Li X; Lin Z; Zhang B; Guo L; Liu S; Li H; Zhang J; Ye Q
Sci Rep; 2016 Feb; 6():21010. PubMed ID: 26867799
[TBL] [Abstract][Full Text] [Related]
13. Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis.
Li J; Qin X; Wu R; Wan L; Zhang L; Liu R
J Cell Mol Med; 2020 May; 24(9):5152-5161. PubMed ID: 32222024
[TBL] [Abstract][Full Text] [Related]
14. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
15. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
[TBL] [Abstract][Full Text] [Related]
16. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway.
Ling S; Li J; Shan Q; Dai H; Lu D; Wen X; Song P; Xie H; Zhou L; Liu J; Xu X; Zheng S
Mol Oncol; 2017 Jun; 11(6):682-695. PubMed ID: 28417539
[TBL] [Abstract][Full Text] [Related]
17. Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Morrow CJ; Ghattas M; Smith C; Bönisch H; Bryce RA; Hickinson DM; Green TP; Dive C
Cancer Res; 2010 Jul; 70(14):5931-41. PubMed ID: 20551056
[TBL] [Abstract][Full Text] [Related]
18. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation.
Ding ZB; Hui B; Shi YH; Zhou J; Peng YF; Gu CY; Yang H; Shi GM; Ke AW; Wang XY; Song K; Dai Z; Shen YH; Fan J
Clin Cancer Res; 2011 Oct; 17(19):6229-38. PubMed ID: 21825039
[TBL] [Abstract][Full Text] [Related]
19. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
20. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
